Summary |
|
||||||||||||
Transgene origin |
|
||||||||||||
Transgene description |
|
||||||||||||
Phenotypes |
View phenotypes and curated references for all genotypes (concatenated display).
|
||||||||||||
Expression |
|
||||||||||||
Find Mice (IMSR) |
|
||||||||||||
Notes |
Transgenic founder lines F26132, F26605, and F26622 were established. The latency of disease was reflective of the level of transgene expression. Founders F26605 and F26622 developed a disease phenotype similar to that observed in MutA trangenics. The high-expressing founder F26605 died early at less than 2 months of age, whereas moderate-expressing founder F26622 died at a later time. Low-expressing founder F26132 did not exhibit a phenotype.
|
||||||||||||
References |
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 10/22/2024 MGI 6.24 |
|
|